成人脓毒性休克中氢化可的松启动时机的评估
单因素分析中各组无血管活性药存活天数无显著差异(中位数0-6小时组3.3天、6-12小时组1.9天、12-24小时组1.9天、24-48小时组0天、>48小时组0天,P=0.39),ICU病死率亦无差异。多因素线性回归显示,与>48小时启动相比,0-6小时启动(β系数2.8天,95%CI 0.8-4.7)、6-12小时启动(2.5天,95%CI 0.2-4.7)和12-24小时启动(2.3天,95%CI 0.2-4.5)与更多无血管活性药存活天数独立相关。多因素逻辑回归显示,与>48小时启动相比,0-6小时启动与ICU病死率降低相关(OR 0.6,95%CI 0.4-0.8)。作者结论认为氢化可的松应在休克发作后12小时内启动。
要点
- 多因素分析中,与>48小时启动氢化可的松相比,0-6小时启动与更多无血管活性药存活天数独立相关(β系数2.8天,95%CI 0.8-4.7)。
- 多因素分析中,与>48小时启动相比,0-6小时启动与ICU病死率降低相关(OR 0.6,95%CI 0.4-0.8)。
- 单因素分析中五组无血管活性药存活天数无显著差异(中位数0-6小时组3.3天、6-12小时组1.9天、12-24小时组1.9天、24-48小时组0天、>48小时组0天,P=0.39),ICU病死率亦无差异。
- 较早启动氢化可的松的患者基线病情更重,APACHE III评分、乳酸浓度和去甲肾上腺素需求量更高。
- 作者结论认为,对因血管活性药依赖型脓毒性休克而处方氢化可的松的患者,应在休克发作后12小时内启动。
适用人群与场景
- 2011至2017年间一家三级学术医疗中心10个内科、外科和神经科学重症监护病房收治的成人患者。
- 纳入血管活性药依赖型脓毒性休克并接受氢化可的松的成人患者。
研究设计与关键结果
- 较早启动氢化可的松的患者基线病情更重,APACHE III评分、乳酸浓度和去甲肾上腺素需求量更高。
- 单因素分析中,各组无血管活性药存活天数无显著差异(中位数0-6小时组3.3天、6-12小时组1.9天、12-24小时组1.9天、24-48小时组0天、>48小时组0天,P=0.39);ICU病死率亦无差异。
- 多因素线性回归中,与>48小时启动相比,0-6小时启动(β系数2.8天,95%CI 0.8-4.7)、6-12小时启动(2.5天,95%CI 0.2-4.7)和12-24小时启动(2.3天,95%CI 0.2-4.5)与更多无血管活性药存活天数独立相关。
- 多因素逻辑回归中,与>48小时启动相比,0-6小时启动与ICU病死率降低相关(OR 0.6,95%CI 0.4-0.8)。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,在因血管活性药依赖型脓毒性休克而处方氢化可的松的患者中,时机至关重要,氢化可的松应在休克发作后12小时内启动。
- 原文多因素分析提示较早启动(0-6、6-12、12-24小时)与>48小时启动相比无血管活性药存活天数更多,0-6小时启动与>48小时启动相比ICU病死率更低;单因素分析中各组无显著差异。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
- 另有 2 条提炼内容因数值无法与原文逐一核对而未列出,请以原文为准。
英文原文(摘要)· 点击展开
INTRODUCTION: Clinical studies evaluating the use of hydrocortisone in patients with septic shock are heterogeneous in design with conflicting results. The appropriate time in which to initiate hydrocortisone after shock onset is unknown. This study sought to compare clinical outcomes including vasopressor duration and mortality in patients with septic shock who received hydrocortisone based on timing of initiation after shock onset.
METHODS: Retrospective cohort study of patients between 2011 and 2017 admitted to 10 medical, surgical, and neurosciences intensive care units (ICUs) at a large, tertiary care academic medical center. Adult patients with vasopressor-dependent septic shock who received hydrocortisone were included. Patients were divided into five timing cohorts based on time after shock onset: 0-6, 6-12, 12-24, 24-48, or >48 h. The primary outcome was days alive and free from vasopressors.
RESULTS: One thousand four hundred seventy patients were included: 567 (38.6%) received hydrocortisone between 0 and 6 h, 231 (15.7%) 6 and 12 h, 260 (17.7%) 12 and 24 h, 195 (13.3%) 24 and 48 h, and 217 (14.8%) >48 h after shock onset. Patients who received hydrocortisone earlier were sicker at baseline with higher APACHE III scores, lactate concentrations, and norepinephrine requirements. On univariate analysis, days alive and free from vasopressors did not significantly differ amongst the timing groups (median 3.3 days for 0-6 h; 1.9 for 6-12 h; 1.9 for 12-24 h; 0 for 24-48 h; 0 for >48 h; P = 0.39); similarly, ICU mortality did not differ. On multivariable linear regression, timing of hydrocortisone was independently associated with more days alive and free from vasopressors when comparing initiation within 0 to 6 h with >48 h (beta-coefficient 2.8 days [95% CI 0.8-4.7]), 6-12 h with >48 h (2.5 days [95% CI 0.2-4.7]), and 12-24 h with >48 h (2.3 days [95% CI 0.2-4.5]). On multivariable logistic regression, timing of hydrocortisone was associated with reduced ICU mortality when comparing receipt within 0 to 6 h of shock onset to >48 h after shock onset (OR 0.6, 95% CI 0.4-0.8).
CONCLUSIONS: In patients in whom hydrocortisone is prescribed for vasopressor-dependent septic shock, timing is crucial and hydrocortisone should be started within the first 12 h after shock onset.
参考来源
- Sacha GL, Chen AY, Palm NM, et al. Evaluation of the Initiation Timing of Hydrocortisone in Adult Patients With Septic Shock. Shock. 2021. PMID: 32890314. doi:10.1097/SHK.0000000000001651
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。